Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05107674
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:21.010625+00:00
Published At
2025-09-09T00:00:00+00:00
Record Updated At
2025-09-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-09"
protocolSection.identificationModule.nctId
"NCT05107674"
protocolSection.identificationModule.officialTitle
"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ovarian Cancer, Epithelial (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • GastroEsophageal Junction (GEJ) Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic or Unresectable Melanoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
  • Metastatic Castration-resistant Prostate Cancer (mCRPC) (protocolSection.conditionsModule.conditions)
  • Malignant Pleural Mesothelioma (MPM) (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (TNBC) (protocolSection.conditionsModule.conditions)
  • Metastatic Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
  • Richter Transformation (protocolSection.conditionsModule.conditions)
  • Microsatellite Stable Colorectal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.